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Abstract: A series of novel alkynyl substituted 3,4-dihydropyrimidin-2(1H)-one (DHPM) 
derivatives were designed, synthesized and evaluated in vitro as potential inhibitors of 
chorismate mutase (CM). All these compounds were prepared via a multi-component 
reaction (MCR) involving sequential I2-mediated Biginelli reaction followed by Cu-free 
Sonogashira coupling. Some of them showed promising inhibitory activities when tested at 
30 µM. One compound showed dose dependent inhibition of CM with IC50 value of 14.76 ± 
0.54 µM indicating o-alkynylphenyl substituted DHPM as a new scaffold for the discovery 
of promising inhibitors of CM.   
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1. Introduction 
Dihydropyrimidinone (DHPM) framework has been found to be integral part of several 
biologically active marine alkaloids [1-4]. Among them, the most potent are the crambine [1] and 
batzelladine [2]. In addition to their potent HIV gp-120 CD4 inhibitory activities [1,5], these 
compounds also showed antiviral, antitumor, antibacterial and anti-inflammatory activities [6,7]. 
Among various DHPM derivatives known the 4-substituted 3,4-dihydropyrimidin-2(1H)-ones 
have attracted particular attention due to their wide range of biological activities [7].
 
They have a 
similar pharmacological profile to that of classical dihydropyridine based calcium channel 
modulators [8-10].
 
Nevertheless, DHPMs have attracted our attention because of the fact that 
several DHPMs have been examined for their antimicrobial properties in the recent years [11-
13]. Structurally, all these derivatives differed with respect to the substituents on the two key 
positions i.e. C-4 and C-5 positions of the dihydropyridine ring.   
Despite the availability of a range of effective antibiotics and drugs, the threat of infectious 
diseases or death due to microbial infections, still poses considerable health problems. 
Tuberculosis (TB) still remains a leading cause of death worldwide due to a number of factors 
such as (a) long duration of treatment (6–9 months), (b) increased incidence of (multi or 
extensive) drug resistance, (c) co-morbidity with HIV-AIDS and (d) declined effort in anti-
infective drug discovery research. Indeed, TB kills more than two million people a year 
worldwide. Thus the discovery [14], development and introduction of new treatments for 
tuberculosis have become an essential goal of current pharmaceutical research. Mycobacterium 
tuberculosis chorismate mutase (*MtbCM or CM) catalyzes the rearrangement of chorismate to 
prephenate in the biosynthetic pathway to form phenylalanine and tyrosine after chorismate 
being formed by the action of chorismate synthase, an enzyme of the shikimate pathway main 
trunk (Fig. 1). In bacteria, MtbCM plays a key role in the synthesis of aromatic amino acids 
necessary for the survival of organism and therefore inhibition of MtbCM may hinder the supply 
of nutrients to the organism. Due to the absence of this pathway in animals but not in bacteria 
CM is considered as a promising target for the identification of new drugs [15]. However, only a 
few small molecules have been reported to possess inhibitory activity against CM [16-18]. In 
continuation of our efforts on the identification of novel inhibitors of CM [19-24]
 
we became 
interested in evaluating the library of small molecules based on 4-substituted 3,4-
dihydropyrimidin-2(1H)-ones B derived from known DHPM framework A (Fig. 2). We 
anticipated that introduction of an alkynyl moiety possessing an appropriate polar / functional  
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Insert Fig. 1 here 
 
 
 
Insert Fig 2 here.  
 
 
 
Insert Fig. 3 here.  
 
 
 
group at the o-position of the C-4 aryl ring may favor the interaction of the resulting molecule 
with the CM protein. This was supported by the docking studies of a representative molecule C 
(glide score = -17.23) which showed H-bonding interactions involving the OH group of the 
alkynyl side chain in addition to the two C=O moieties (of the central ring and ester) with Arg49, 
Lys60, Glu109 and Gln76 residues of the chorismate mutase protein (Fig. 3). Notably, shifting of 
the alkynyl moiety from o- to m- or p- position or its complete removal decreased the 
interactions with the protein in silico. These observations strengthened our initial thought on 
focusing on B containing alkynyl moiety at the o-position of the C-4 aryl ring. Herein we report 
our preliminary findings on the CM inhibiting properties of a series of alkynyl substituted 
DHPM derivatives in vitro. To the best of our knowledge this is the first report that discloses 
DHPM derivatives as potential inhibitors of CM. 
 
2. Results and discussion 
2.1. Chemistry 
Generally, DHPM derivatives are conveniently prepared via a widely used multi component 
reaction (MCR), called Biginelli reaction [25]
 
that
 
involves the cyclocondensation of an 
aldehyde, a β-ketoester, and urea (or thiourea) to give dihydropyrimidin-2(1H)-ones (or thio 
analogues) [6,7]. A large number of reports are now available on Biginelli reaction [9] to 
improve the reaction conditions and product yields along with variations in all three reactants. 
Recently, we have explored further application of Biginelli reaction beyond three component 
limit. Thus, an overall four component reaction was developed involving a sequential 
phosphorous acid-mediated Biginelli followed by Cu-free Sonogashira or Heck or Suzuki 
reaction [26]. The use of elemental iodine on the other hand has been explored for successful 
Biginelli reaction earlier [27]. In view of the easy availability and inexpensive as well as safer  
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Insert Scheme 1 here.  
 
 
nature of I2 we modified our earlier strategy by replacing the phosphorous acid with I2 and 
found that the new strategy worked well (vide infra). We therefore used this modified 
method to synthesize our target alkynyl derivatives B (or 5, Scheme 1) that were designed for 
the potential inhibition of CM. Thus, a mixture of aldehyde 1 (1.0 mmol), ethyl or t-butyl or 
methyl acetoacetate 2 (5.0 mL), urea 3 (1.25 mmol) and I2 (10 mol %) was stirred at room 
temperature for 5 min. Subsequently, the reaction mixture was heated to 100-120 °C for 1-2 
h and then cooled to 50 °C. To this was added pyrrolidine (3 mL), PdCl2(PPh3)2 (2 mol%) 
and the alkyne 4 (1.5 mmol) with stirring and the mixture was stirred at 80-85 °C for 1-2 h. 
After usual work up and purification the desired product 5 was isolated in good yield. All the 
compounds synthesized were well characterized by IR absorbsions near 2227 (-C≡C-), 1700 
(C=O) and 1650 (C=O) cm
-1 
and appearance of a peak near δ 5.6 corresponding to C-4 
hydrogen [24].  
 
2.2. Pharmacology 
All the synthesized DHPM derivatives were tested for their inhibitory potential against 
Mycobacterium tuberculosis H37Rv chorismate mutase (CM). The assay [28,29] involved 
determination of activity of enzyme CM which catalyzes the conversion of chorismate to 
prephenate. Thus determination of activity of CM is based on the direct observation of 
conversion of chorismic acid to prephenate spectrophotometrically at OD274. This reaction 
was performed in the presence of test compounds to determine their CM inhibiting activities. 
A known inhibitor of CM i.e. 4-(3,5-dimethoxyphenethylamino)-3-nitro-5-sulfamoylbenzoic 
acid [16] was prepared and used as a reference compound the IC50 value of which was found 
to be less than 10 µM. Compounds 5c, 5d, 5e and 5f showed 60, 41, 63 and 57% inhibition 
of CM compared to other molecules when tested (see ESI for the procedure) at 30 µM (Table 
1) whereas rest of the compounds were either less active or inactive. Notably, compounds 
containing alkynyl side chain possessing a hydroxy group showed superior activities than 
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others. A hydrophobic chain or a bulky group at the alkynyl moiety was found to be 
unfavorable for activities. In general, a bulky ester group attached to the central DHPM ring 
(e.g. 5k-m) was also found to be unfavorable. Based on the preliminary data generated 
compound 5e was chosen for further evaluation in vitro. In a dose response study, compound 
5e showed inhibition of CM in a dose dependent manner with an IC50 value of 14.76 ± 0.54 
µM (Fig. 4). Thus, alkynyl substituted DHPM framework appeared as a new scaffold for the 
development of novel inhibitors of chorismate mutase. Since tuberculosis is a leading cause 
of death worldwide, the present class of compounds are of further interest as potential 
antitubercular agents.  
 
 
Insert Table 1 here.  
 
 
 
 
 
Insert Fig. 4 here.  
 
3. Conclusions  
In conclusion, we have described the design, synthesis and in vitro evaluation of novel o-
alkynylphenyl substituted 3,4-dihydropyrimidin-2(1H)-one derivatives as potential inhibitors 
of chorismate mutase. A series of small molecules synthesized via a MCR involving 
sequential iodine-mediated solvent-free Biginelli reaction followed by copper-free 
Sonogashira coupling in a single pot were screened against CM. Some of them showed 
promising inhibitory activities when tested at 30 µM and one compound showed dose 
dependent inhibition of CM with IC50 value of 14.76 ± 0.54 µM. Overall, this research has 
identified alkynyl substituted DHPM as a new scaffold for the development of new inhibitors 
of chorismate mutase.   
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Figure captions  
Fig. 1. Conversion of chorismate to prephanate by CM in the shikimate pathway 
 
Fig 2. Design of DHPM based novel inhibitors of chorismate mutase 
 
Fig. 3. Docking of molecule C into CM (PDB code-2FP2) 
 
Fig. 4. Dose dependent inhibition of CM by the compound 5e 
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Figures  
 
Fig. 1.  
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Fig. 3.  
 
 
 
 
 
 
Fig. 4.  
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5 % yield 
n-Hexyl Et 5a 85 
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-CH2OH Et 5c 84 
-CH(OH)CH3 Et 5d  80 
-(CH2)2OH Et 5e 83 
-(CH2)3OH Et 5f 85 
1-cyclohexenyl Et 5g 90 
1-hydroxycyclohexanyl Et 5h 86 
phenyl Et 5i  81 
4-(n-pentyl)phenyl Et 5j 85 
n-Pentyl  t-Bu 5k 87 
1-cyclohexenyl t-Bu 5l 82 
1-hydroxycyclohexanyl t-Bu 5m 84 
1-hydroxycyclohexanyl Me 5n 82 
1-cyclohexenyl Me 5o 81 
n-Hexayl Me 5p 84 
4-Methyl phenyl Me 5q 83 
 
Scheme 1. Synthesis of o-alkynylphenyl substituted dihydropyrimidin-2(1H)-one derivatives (5) 
via a MCR involving sequential iodine-mediated Biginelli reaction followed by Cu-free 
Sonogashira coupling.  
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Table 1. Inhibition of chorismate mutase by compound 5 in vitro.  
Entry Compound 5 % inhibition @ 30 µM
 
 
1.  
 
5a 
 
 
31 
2.  
        
5b 
 
 
29 
3.  
N
H
NH
O
OH
O
EtO
          
5c 
 
 
60 
4.  
N
H
NH
O
EtO2C
OH
        
5d 
 
41 
 
5.  
       
5e 
 
63 
6.  
  
5f 
 
57 
7.  
      
 
27 
  
   
14 
 
5g 
8.  
      
5h 
 
 
20 
9.  
      
5i 
 
 
17 
10.  
N
H
NH
O
EtO2C
   
5j 
 
 
19 
11.  
  
5k 
 
 
30 
12.  
        
5l 
 
 
22 
13.  
    
5m 
 
 
18 
14.  
N
H
NH
MeO2C
O
OH
 
5n 
 
25 
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15.  
N
H
NH
MeO2C
O
 
5o 
 
21 
16.  
N
H
NH
MeO2C
O
CH3
 
5p 
 
28 
17.  
N
H
NH
MeO2C
O
CH3
 
5q 
 
16 
 
a
Data presented are
 
average of three experiments. 
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Highlights 
 
 Alkynyl substituted DHPMs are synthesized via an alternative MCR.  
 The MCR involved I2-mediated Biginelli followed by Sonogashira reaction.  
 These compounds showed chorismate mutase (CM) inhibitory properties in vitro.  
 One compound showed dose dependent inhibition of CM (IC50 ~ 14.76 ± 0.54 µM) 
 
 
